Assembly Biosciences (ASMB) said Monday interim Phase 1b results showed its weekly oral candidate ABI-1179 cut HSV-2 shedding by 98% and virologically confirmed genital lesion rates 91% versus placebo.
The company said its monthly oral ABI-5366 regimen reduced Herpes Simplex Virus-2 shedding by 76% and virologically confirmed lesion rates by 88%.
Both candidates were reported as well-tolerated with no serious adverse events.
Shares of the company were up 3.73% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.